I help medical device companies prepare ISO 10993 biological evaluation documentation — BEP, BER, and TRA — that satisfies notified body and FDA reviewers. Real science. Not templated reports.
Biocompatibility Consultant
Expertise across global regulatory frameworks
If your device touches, implants into, or communicates with the human body — I can prepare the biological evaluation documentation.
Long-term and permanent implants — the most demanding biocompatibility category requiring full endpoint coverage and genotoxicity assessment.
Surface-contacting devices with intact or compromised skin contact. Biocompatibility assessment for wound care materials and dressings.
Short and long-term blood/tissue contact devices. Chemical characterization, extractables assessment, and TRA for polymeric materials.
Oral contact devices including restorative materials, surgical instruments, and orthodontic devices requiring ISO 10993 biological evaluation.
Blood-contacting devices with critical biocompatibility requirements including thrombogenicity and haemocompatibility endpoint evaluation.
Devices that contact the patient during diagnostic procedures — biosensors, imaging probes, and electrochemical sensors.
Bone-contacting implants and fixation devices requiring genotoxicity, implantation, and systemic toxicity endpoint evaluation.
Devices in contact with ocular tissue — a sensitive contact category requiring careful material selection and cytotoxicity evaluation.
Not sure if your device fits? Send me a brief description — I'll confirm scope and timeline within 24 hours, no obligation.
Medical device companies face recurring biological evaluation challenges. I specialize in resolving each one.
Your notified body flagged gaps in your biological evaluation plan or report. I prepare structured, scientifically justified responses.
ISO 10993-1 allows test waivers with proper justification. I identify which endpoints can be justified and prepare the scientific rationale.
MedTech startups preparing their first biological evaluation documentation. I build scientifically defensible BEPs from scratch.
Your biocompatibility section was rejected or flagged by FDA. I prepare FDA-aligned documentation per the 2020 ISO 10993 guidance.
Device material or design change triggers a biocompatibility re-evaluation. I perform change impact assessments aligned with ISO 10993-1.
ISO 10993-1:2025 introduced lifecycle approach changes. I perform gap analysis and update legacy documentation to current requirements.
Comprehensive biological evaluation and regulatory documentation services for medical device submissions.
ISO 10993-1:2018/2025 compliant endpoint strategy. Delivered in 3–5 business days.
ISO 10993-1:2025Literature evaluation, existing data assessment, risk-based conclusions. 5–7 business days.
ISO 10993-1:2025AET/TTC calculations per ISO 10993-17 and ISO 10993-18 for extractables and leachables.
ISO 10993-17/18Assess existing BEP/BER documentation against the updated 2025 requirements. Identify and resolve gaps.
2025 UpdateExpert audit of your documentation before notified body or FDA submission to identify issues proactively.
Pre-submissionAnnex I GSPR §10 compliant documentation for CE Mark technical file submission.
EU MDRPer FDA ISO 10993 guidance (2020). Structured biocompatibility summary aligned to FDA reviewer expectations.
FDA 510(k)MEDDEV 2.7/1 Rev.4 compliant clinical evaluation reports for EU MDR CE Mark submissions.
EU MDRPMCF Plan and Report documentation plus PMS documentation aligned to EU MDR requirements.
Post-MarketScientific manuscript writing and editing for biomedical journals. Published in Bioelectrochemistry (Elsevier) and Advanced Sensor Research (Wiley).
PublicationPRISMA-structured systematic literature reviews for biological evaluation and clinical evaluation reports.
PRISMAWhite papers, technical summaries, and grant proposals for MedTech R&D and regulatory strategy.
Technical WritingI have personally conducted cytotoxicity assays, studied inflammatory responses to biomaterials, and published research on biological evaluation endpoints. With 10+ years in biomaterials science and hands-on bench experience, when I write your BER, I understand the science behind each endpoint — not just the regulatory requirement.
Hands-on cytotoxicity, oxidative stress, and biomaterial–cell interaction research at INSERM U1026 Biotis, Bordeaux, France under Marie Skłodowska-Curie Fellowship (Horizon 2020).
Deep knowledge of the 2025 revision — lifecycle approach, explicit benefit-risk determination, test waiver justification, and legacy BEP/BER gap analysis. I build documentation that passes first review.
PhD research on implantable electrochemical biosensors at IIT Kanpur — covering the most demanding biocompatibility category: long-term implant contact, genotoxicity, and chronic toxicity pathways.
BEP in 3–5 business days. BER in 5–7 business days. Delivered in Word and PDF with one revision included. Available across EU, US, and Asia-Pacific time zones.
GATE qualified (top national engineering exam, India). AICTE National Doctoral Fellowship recipient. Animal cell culture certified — CCMB, Hyderabad. Upwork Verified & ID Verified.
ISO 10993 Biocompatibility Consultant
A clear, structured process from first contact to submission-ready documentation.
We discuss your device, material, contact category, and submission timeline. No obligation. I respond within 24 hours.
I define the documentation scope, endpoint strategy, and deliverables. Clear timeline and fixed price quote.
I prepare scientifically grounded BEP/BER/TRA documentation aligned to your regulatory target (EU MDR or FDA).
You review the draft, provide feedback, and I finalize. Delivered in Word and PDF. One revision included.
Anonymized project outcomes across device types and regulatory pathways. Specific details withheld under client confidentiality.
Electrochemical glucose sensor for long-term subcutaneous implantation. Prepared full BEP and BER covering 14 ISO 10993 endpoints including genotoxicity and chronic toxicity. Notified body accepted documentation without additional information request.
FDA issued an additional information request citing incomplete cytotoxicity extract rationale and missing chemical characterization for the polymeric hub. Prepared targeted response document with AET calculations and test waiver justifications. 510(k) clearance received.
MedTech startup with an existing BER prepared under ISO 10993-1:2018. Performed gap analysis against the 2025 revision requirements. Identified 3 documentation gaps including missing benefit-risk determination language and lifecycle approach framing. Updated BER sections delivered.
Titanium-alloy bone fixation plate with polymeric coating. Performed ISO 10993-17/18 compliant TRA including chemical characterization of coating extractables, AET thresholds, and TTC-based waiver justification for three compounds below detection limits.
First-time EU MDR submission for a zirconia dental implant. Drafted the complete Annex I GSPR §10 biocompatibility section including BEP, BER, and risk management integration. Notified body confirmed documentation was complete at initial technical review.
Manufacturer changed hub material from ABS to a medical-grade polycarbonate blend. Performed ISO 10993-1:2025 change impact assessment, documented chemical equivalence rationale, and confirmed no new testing required. Updated BER section ready for 510(k) amendment filing.
Three clear engagement paths. Pick the one that matches your situation — or contact me and I'll recommend the right scope.
You have existing BEP / BER / TRA — you need an expert check before submission
You need a complete BEP, BER, or TRA written from scratch
FDA or notified body flagged your documentation — you need a targeted, fast response
Book a free 15-minute call. I'll listen to your situation and tell you exactly what scope is needed — no upselling, no obligation.
Expert articles on ISO 10993, EU MDR and FDA biocompatibility — written by a practising consultant, not a template library.
The 2025 revision fundamentally reframes how biological safety must be evaluated across the entire device lifecycle.
These two documents are consistently confused in submissions. Here is the definitive distinction and the most common mistake.
FDA additional information requests for biocompatibility are among the most common 510(k) delays. Avoid all five patterns.
Whether you're preparing an initial BEP, responding to a notified body query, or updating legacy documentation to ISO 10993-1:2025 — I offer a free 15-minute introductory call to understand your project before any engagement.
I respond within 24 hours on business days